NasdaqGM - Delayed Quote USD

Merus N.V. (MRUS)

Compare
39.56
+4.67
+(13.38%)
At close: 4:00:04 PM EDT
39.56
0.00
(0.00%)
After hours: 5:01:03 PM EDT
Advanced Chart
Loading Chart for MRUS
  • Previous Close 34.89
  • Open 34.08
  • Bid 39.19 x 100
  • Ask 39.86 x 100
  • Day's Range 33.19 - 40.00
  • 52 Week Range 33.19 - 61.61
  • Volume 994,545
  • Avg. Volume 722,449
  • Market Cap (intraday) 2.733B
  • Beta (5Y Monthly) 1.03
  • PE Ratio (TTM) --
  • EPS (TTM) -3.35
  • Earnings Date May 6, 2025 - May 12, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 87.20

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

www.merus.nl

260

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

More about Merus N.V.

Recent News: MRUS

View More
View More

Performance Overview: MRUS

Trailing total returns as of 4/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

MRUS
5.92%
S&P 500 (^GSPC)
7.22%

1-Year Return

MRUS
7.68%
S&P 500 (^GSPC)
4.74%

3-Year Return

MRUS
41.29%
S&P 500 (^GSPC)
21.58%

5-Year Return

MRUS
226.94%
S&P 500 (^GSPC)
95.60%

Compare To: MRUS

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

MRUS
Merus N.V.
39.56
+13.38%
Mkt Cap 2.733B
Industry Biotechnology
NUVL
Nuvalent, Inc.
64.70
+9.07%
Mkt Cap 4.632B
Industry Biotechnology
SRRK
Scholar Rock Holding Corporation
27.06
+10.58%
Mkt Cap 2.562B
Industry Biotechnology
APGE
Apogee Therapeutics, Inc.
31.80
+10.46%
Mkt Cap 1.847B
Industry Biotechnology
ACLX
Arcellx, Inc.
59.16
+10.37%
Mkt Cap 3.25B
Industry Biotechnology
AKRO
Akero Therapeutics, Inc.
37.36
+9.75%
Mkt Cap 2.975B
Industry Biotechnology
PTGX
Protagonist Therapeutics, Inc.
42.57
+2.16%
Mkt Cap 2.613B
Industry Biotechnology
CRNX
Crinetics Pharmaceuticals, Inc.
27.66
+8.22%
Mkt Cap 2.574B
Industry Biotechnology
XENE
Xenon Pharmaceuticals Inc.
31.59
+11.90%
Mkt Cap 2.418B
Industry Biotechnology
JANX
Janux Therapeutics, Inc.
26.83
+12.78%
Mkt Cap 1.586B
Industry Biotechnology
SWTX
SpringWorks Therapeutics, Inc.
37.12
+3.95%
Mkt Cap 2.783B
Industry Biotechnology

Statistics: MRUS

View More

Valuation Measures

Annual
As of 4/8/2025

  • Market Cap

    2.41B

  • Enterprise Value

    1.88B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    62.01

  • Price/Book (mrq)

    3.72

  • Enterprise Value/Revenue

    52.13

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -27.47%

  • Return on Equity (ttm)

    -42.88%

  • Revenue (ttm)

    36.13M

  • Net Income Avi to Common (ttm)

    -215.33M

  • Diluted EPS (ttm)

    -3.35

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    537.03M

  • Total Debt/Equity (mrq)

    1.53%

  • Levered Free Cash Flow (ttm)

    -123.22M

View More

Research Analysis: MRUS

View More
View More

Company Insights: MRUS

Research Reports: MRUS

View More
View More

People Also Watch

CRNX Crinetics Pharmaceuticals, Inc.
27.66
+8.22%
 
IDYA IDEAYA Biosciences, Inc.
15.78
+8.83%
 
SNDX Syndax Pharmaceuticals, Inc.
11.52
+9.09%
 
PTGX Protagonist Therapeutics, Inc.
42.57
+2.16%
 
XENE Xenon Pharmaceuticals Inc.
31.59
+11.90%
 
KRYS Krystal Biotech, Inc.
168.16
+5.97%
 
KURA Kura Oncology, Inc.
5.97
+6.23%
 
RYTM Rhythm Pharmaceuticals, Inc.
60.23
+4.33%
 
REPL Replimune Group, Inc.
7.31
+2.38%
 
KYMR Kymera Therapeutics, Inc.
23.95
+13.78%
 
XNCR Xencor, Inc.
8.81
+14.86%
 
BCYC Bicycle Therapeutics plc
6.88
+7.84%
 
KROS Keros Therapeutics, Inc.
10.33
+5.84%
 
YMAB Y-mAbs Therapeutics, Inc.
4.4500
+8.80%
 
MIRM Mirum Pharmaceuticals, Inc.
41.47
+5.47%
 
PCVX Vaxcyte, Inc.
30.80
+1.99%